Concise review: Prospects of bone marrow mononuclear cells and mesenchymal stem cells for treating status epilepticus and chronic epilepsy

Stem Cells

Volumn 33, Issue 7, 2015, Pages 2093-2103

  Agadi, Satish ^a   Shetty, Ashok K ^a,b,c  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Bone marrow stromal cells; Cell transplantation; Experimental models; Mesenchymal stem cells; Nervous system; Neural stem cell; Stem cell transplantation; Tissue regeneration

Indexed keywords

ALTERNATIVE MEDICINE; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CELL THERAPY; COGNITION; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; INFLAMMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE DEGENERATION; NONHUMAN; UMBILICAL CORD BLOOD; ANIMAL; BONE MARROW CELL; CHRONIC DISEASE; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES; STATUS EPILEPTICUS; TISSUE REGENERATION;

ANIMALIA;

ANIMALS; BONE MARROW CELLS; CHRONIC DISEASE; EPILEPSY; GUIDED TISSUE REGENERATION; HUMANS; MESENCHYMAL STROMAL CELLS; STATUS EPILEPTICUS;

EID: 84931574139     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2029     Document Type: Article

References (88)

1. Meinardi H, Scot RA, Reis R, et al., The treatment gap in epilepsy: The current situation and ways forward. Epilepsia 2001; 42: 136-149.
2. Kwan P, Brodie MJ,. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
3. Perry MS, Duchowny M,. Surgical versus medical treatment for refractory epilepsy: Outcomes beyond seizure control. Epilepsia 2013; 54: 2060-2070.
4. Cervenka MC, Kosoff EH,. Dietary treatment of intractable epilepsy. Continuum 2013; 19: 756-766.
5. Fisher RS,. Deep brain stimulation for epilepsy. Handb Clin Neurol 2013; 116: 217-234.
6. Morris GL 3rd, Gloss D, Buchhalter J, et al., Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the guideline development subcommittee of the American Academy of Neurology. Epilepsy Curr 2013; 13: 297-303.
7. Löscher W, Gernet M, Heinemann U,. Cell and gene therapies in epilepsy-Promising avenues or blind alleys? Trends Neurosci 2008; 31: 62-73.
8. Shetty AK,. Progress in cell grafting therapy for temporal lobe epilepsy. Neurotherapeutics 2011; 8: 721-735.
9. Shen HY, Sun H, Hanthorn MM, et al., Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice. J Neurosurg 2014; 120: 628-638.
10. Kullmann KM, Schorge S, Walker MC, et al., Gene therapy in epilepsy-Is it time for clinical trials? Nat Rev Neurol 2014; 10: 300-304.
11. Noè F, Pool AH, Nissien J, et al., Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008; 131: 1506-1515.
12. Shetty AK, Zaman V, Hattiangady B,. Repair of the injured adult hippocampus through graft-mediated modulation of the plasticity of the dentate gyrus in a rat model of temporal lobe epilepsy. J Neurosci 2005; 25: 8391-8401.
13. Walker MC, Schorge S, Kullmann DM, et al., Gene therapy in status epilepticus. Epilepsia 2013; 54: 43-45.
14. Riban V, Fitzsimons HL, During MJ,. Gene therapy in epilepsy. Epilepsia 2009; 50: 24-32.
15. Shetty AK,. Hippocampal injury-induced cognitive and mood dysfunction, altered neurogenesis, and epilepsy: Can early neural stem cell grafting intervention provide protection? Epilepsy Behav 2014; 38: 117-124.
16. Hattiangady B, Rao MS, Shetty AK,. Grafting of striatal precursor cells into hippocampus shortly after status epilepticus restrains chronic temporal lobe epilepsy. Exp Neurol 2008; 212: 468-481.
17. Baraban SC, Southwell DG, Estrada RC, et al., Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. Proc Natl Acad Sci USA 2009; 106: 15472-15477.
18. Waldau B, Hattiangady B, Kuruba R, et al., Medial ganglionic eminence-derived neural stem cell grafts ease spontaneous seizures and restore GDNF expression in a rat model of chronic temporal lobe epilepsy. Stem Cells 2010; 28: 1153-1164.
19. Hunt RF, Girskis KM, Rubenstein JL, et al., GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. Nat Neurosci 2013; 16: 692-697.
20. Southwell DG, Nicholas CR, Basbaum AL, et al., Interneurons from embryonic development to cell-based therapy. Science 2014; 344: 1240622.
21. Cunningham M, Cho JH, Leung A, et al., hPSC-derived maturing GABA-ergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. Cell Stem Cell 2014; 14: 559-573.
22. Rao MS, Hattiangady B, Rai KS, et al., Strategies for promoting anti-seizure effects of hippocampal fetal cells grafted into the hippocampus of rats exhibiting chronic temporal lobe epilepsy. Neurobiol Dis 2007; 27: 117-132.
23. Cunningham JJ, Ulbright TM, Pera MF, et al., Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 2012; 30: 849-857
24. Karussis D, Kassis I, Kurkalli BG, et al., Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008; 265: 131-135.
25. Ding D, Shyu WC, Lin SZ,. Mesenchymal stem cells. Cell Transplant 2011; 20: 5-14.
26. Vaquero J, Zurita M,. Functional recovery after severe CNS trauma: Current perspectives for cell therapy with bone marrow stromal cells. Prog Neurobiol 2011; 93: 341-349.
27. Slavin S, Kurkalli BG, Karussis D,. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 2008; 110: 943-946.
28. Yamout B, Hourani R, Salti H, et al., Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010; 227: 185-189.
29. Ben-Hur T,. Cell therapy for multiple sclerosis. Neurotherapeutics 2011; 8: 625-642.
30. Kocsis JD, Honmou O,. Bone marrow stem cells in experimental stroke. Prog Brain Res 2012; 201: 79-98.
31. Drago D, Cossetti C, Iraci N, et al., The stem cell secretome and its role in brain repair. Biochimie 2013; 95: 2271-2285.
32. Allers C, Jones JA, Lasala GP, et al., Mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis: Signals for hope? Regen Med 2014; 9: 637-647.
33. Yang N, Wemig M,. Harnessing the stem cell potential: A case for neural stem cell therapy. Nat Med 2013; 19: 1580-1581.
34. Prockop DJ, Prockop SE, Bertoncello I,. Are clinical trials with mesenchymal stem/ progenitor cells (MSCs) too far ahead of the science? Lessons from experimental hematology. Stem Cells 2014; 32: 3055-3061.
35. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al., Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67: 1 187-1194.
36. Trounson A, Thakar RG, Lomax G, et al., Clinical trials for stem cell therapies. BMC Med 2011; 9: 52.
37. Lalu MM, McIntyre L, Pugliese C, et al., Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLOS One 2012; 7: e47559.
38. Donega V, Nijboer CH, van Tilborg G, et al., Intranasally administered mesenchymal stem cells promote a regenerative niche for repair of neonatal ischemic brain injury. Exp Neurol 2014; 261C: 53-64.
39. Forostyak S, Homola A, Turnovcova K, et al., Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS. Stem Cells 2014; 32: 3163-3172.
40. Oh JY, Kim TW, Jeong HJ, et al., Intraperitoneal infusion of mesenchymal stem/stromal cells prevents experimental autoimmune uveitis in mice. Mediators Inflamm 2014; 2014: 624640
41. Ohshima M, Taguchi A, Tsuda H, et al., Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev 2015; 37: 376-386.
42. Lim MH, Ong WK, Sugai S,. The current landscape of adipose-derived stem cells in clinical applications. Exp Rev Mol Med 2014; 16: e8
43. Liu J, Yu F, Sun Y, et al., Characteristics and potential applications of human dental tissue derived mesenchymal stem cells. Stem Cells 2015; 33: 627-638.
44. Watson N, Divers R, Kedar R, et al., Discarded Wharton jelly of the human umbilical cord: A viable source of mesenchymal stromal cells. Cytotherapy 2015; 17: 18-24.
45. Kimbrel EA, Louris NA, Yavanian GJ, et al., Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev 2014; 23: 1611-1624.
46. Riviello JJ Jr, Ashwal S, Hirtz D, et al., Practice parameter: Diagnostic assessment of the child with status epilepticus (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2006; 67: 1542-1550.
47. McMullan JT, Knight WA, Clark JF, et al., Time-critical neurological emergencies: The unfulfilled role for point-of-care testing. Int J Emerg Med 2010; 3: 127-131.
48. Gastaut JL, Bartolomei F,. Partial epilepsy and corpus callosum involvement. Rev Neurol (Paris) 1993; 149: 416-418
49. Treatment of convulsive e status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270: 854-859.
50. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993; 34: 592.
51. DeLorenzo R, Hauser WA, Towne AR, et al., A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46: 1029-1035.
52. Meldrum BS, Brierley JB,. Prolonged epileptic seizures in primates: Ischemic cell change and its relation to ictal physiological events. Arch Neurol 1973; 28: 10-17.
53. Meldrum BS,. Metabolic factors during prolonged seizures and their relation to nerve cell death. Adv Neurol 1983; 34: 261-275.
54. Maytal J, Shinnar S, Moshe SL, et al., Low morbidity and mortality of status epilepticus in children. Pediatrics 1989; 83: 323-331.
55. Wu Y, Shek DW, Garcia PA, et al., Incidence and mortality of generalized convulsive status epilepticus in California. Neurology 2002; 58: 1070-1076.
56. Chin RF, Neville BG, Peckham C, et al., Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: Prospective population-based study. Lancet 2006; 368: 222-229.
57. Raspall-Chaure M, Chin RF, Neville BG, et al., Outcome of paediatric convulsive status epilepticus: A systematic review. Lancet Neurol 2006; 5: 769-779.
58. Roy H, Lippe S, Lussier F, et al., Developmental outcome after a single episode of status epilepticus. Epilepsy Behav 2011; 21: 430-436.
59. Martinos MM, Yoong M, Patil S, et al., Recognition memory is impaired in children after prolonged febrile seizures. Brain 2012; 135: 3153-3164.
60. Martinos MM, Yoong M, Patil S, et al., Early developmental outcomes in children following convulsive status epilepticus: A longitudinal study. Epilepsia 2013; 54: 1012-1019.
61. Sahin M, Menache CC, Holmes GL, et al., Outcome of severe refractory status epilepticus in children. Epilepsia 2001; 42: 1461-1467.
62. Mayer SA, Claassen J, Lokin J, et al., Refractory status epilepticus: Frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59: 205-210.
63. Pitkänen A, Lukasiuk K,. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011; 10: 173-186.
64. Patterson KP, Baram TZ, Shinnar S,. Origins of temporal lobe epilepsy: Febrile seizures and febrile status epilepticus. Neurotherapeutics 2014; 11: 242-250.
65. Lukasiuk K, Becker AJ,. Molecular biomarkers of epileptogenesis. Neurotherapeutics 2014; 11: 319-323.
66. Sloviter RS, Bumanglag AV,. Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology 2013; 69: 3-15.
67. Costa-Ferro ZS, Vitola AS, Pedroso MF, et al., Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy. Seizure 2010; 19: 84-92.
68. Leal MM, Costa-Ferro ZS, Souza BS, et al., Earl transplantation of bone marrow mononuclear cells promotes neuroprotection and modulation of inflammation after status epilepticus in mice by paracrine mechanisms. Neurochem Res 2014; 39: 259-268.
69. Costa-Ferro ZS, de Borba Cunha F, de Freitas Souza BS, et al., Antiepileptic and neuroprotective effects of human umbilical cord blood mononuclear cells in a pilocarpine-induced epilepsy model. Cytotechnology 2014; 66: 193-199.
70. Posel C, Moller K, Frohlich W, et al., Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One 2012; 7: e50293.
71. Voulgari-Kokota A, Fairless R, Karamita M, et al., Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol 2012; 236: 161-170.
72. Abdanipour A, Tiraihi T, Mirnajafi-Zadeh J,. Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell therapy. Neurol Res 2011; 33: 625-632.
73. Shetty AK, Hattiangady B, Shetty G, et al., Intraperitoneal administration of human mesenchymal stem cells restrains status epilepticus induced neurodegeneration and inflammatory reaction in the hippocampus. Abstracts of the 12th Annual meeting of International Society for Stem Cell Research, 2014: F-3145.
74. Li T, Ren G, Kaplan DL, et al., Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. Epilepsy Res 2009; 84: 238-241.
75. Long Q, Qiu B, Wang K, et al., Genetically engineered bone marrow mesenchymal stem cells improve functional outcome in a rat model of epilepsy. Brain Res 2013; 1532: 1-13.
76. Uccelli A, Prockop DJ,. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 2010; 22: 768-774.
77. Houser CR,. Do structural changes in GABA neurons give rise to the epileptic state? Adv Exp Med Biol 2014; 813: 151-160.
78. Shetty AK, Hattiangady B,. Concise review: Prospects of stem cell therapy for temporal lobe epilepsy. Stem Cells 2007; 25: 2396-2407.
79. Shetty AK,. Neural stem cell therapy for temporal lobe epilepsy. In:, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delagrado-Escueta AV, eds. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th ed. Bethesda (MD): National Center for Biotechnology Information, 2012; PMID: 22787648
80. Maisano X, Litvina E, Taqliatela S, et al., Differentiation and functional incorporation of embryonic stem cell-derived GABAergic interneurons in the dentate gyrus of mice with temporal lobe epilepsy. J Neurosci 2012; 32: 46-61.
81. Venturin GT, Greggio S, Marinowic DR, et al., Bone marrow mononuclear cells reduce seizure frequency and improve cognitive outcome in chronic epileptic rats. Life Sci 2011; 89: 229-234.
82. Costa-Ferro ZS, Souza BS, Leal MM, et al., Transplantation of bone marrow mononuclear cells decreases seizure incidence, mitigates neuronal loss and modulates pro-inflammatory cytokine production in epileptic rats. Neurobiol Dis 2012; 46: 302-313.
83. Huicong K, Zheng X, Furong W, et al., The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 2013; 48: 921-930.
84. Melvin JJ, Huntley Hardison H,. Immunomodulatory treatments in epilepsy. Semin Pediatr Neurol 2014; 21: 232-237.
85. Battiwalla M, Barrett AJ,. Bone marrow mesenchymal stromal cells to treat complications following allogenic stem cell transplantation. Tissue Eng Part B Rev 2014; 20: 211-217.
86. Karlupia N, Manley NC, Prasad K, et al., Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model. Stem Cell Res Ther 2014; 5: 45.
87. Cui L, Kerkelä E, Bakreen A, et al., The cerebral embolism evoked by intra-areterial delivery of allogenic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther 2015; 6: 11.
88. Chua JY, Pendharkar AV, Wang N, et al., Intra-arterial injection of neural stem cells using a microneedle technique does not cause microembolic strokes. J Cerebr Blood Flow Metab 2011; 31: 1263-1271.